| 000 | 01663 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518062018.0 | ||
| 264 | 0 | _c20200204 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1422-0067 | ||
| 024 | 7 |
_a10.3390/ijms20194710 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIn 't Veld, Aliede E | |
| 245 | 0 | 0 |
_aImmunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring? _h[electronic resource] |
| 260 |
_bInternational journal of molecular sciences _cSep 2019 |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntigens, CD _ximmunology |
| 650 | 0 | 4 |
_aCD40 Ligand _ximmunology |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-gamma _ximmunology |
| 650 | 0 | 4 |
_aInterleukin-2 _ximmunology |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPhytohemagglutinins _xpharmacology |
| 650 | 0 | 4 |
_aReceptors, Transferrin _ximmunology |
| 650 | 0 | 4 |
_aTacrolimus _xadministration & dosage |
| 700 | 1 | _aGrievink, Hendrika W | |
| 700 | 1 | _aSaghari, Mahdi | |
| 700 | 1 | _aStuurman, Frederik E | |
| 700 | 1 | _ade Kam, Marieke L | |
| 700 | 1 | _ade Vries, Aiko P J | |
| 700 | 1 | _ade Winter, Brenda C M | |
| 700 | 1 | _aBurggraaf, Jacobus | |
| 700 | 1 | _aCohen, Adam F | |
| 700 | 1 | _aMoerland, Matthijs | |
| 773 | 0 |
_tInternational journal of molecular sciences _gvol. 20 _gno. 19 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3390/ijms20194710 _zAvailable from publisher's website |
| 999 |
_c30138013 _d30138013 |
||